What is Zacks Research's Forecast for PBH Q2 Earnings?

Key Points

• Zacks Research forecasts Q2 FY2027 EPS of $1.06 for Prestige Consumer Healthcare and maintains a “Hold” rating.
• Its full-year FY2027 EPS estimate is $4.55, broadly in line with the $4.56 consensus, while forecasts rise to $5.06 for FY2028 and $5.25 for FY2029.
• Prestige recently exceeded expectations, reporting quarterly EPS of $0.98 versus $0.89 expected and revenue of $265.71 million versus $253.02 million, with sales up 6.5% year over year.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Analysts at Zacks Research issued their Q2 2027 earnings estimates for Prestige Consumer Healthcare in a research report issued on Tuesday, August 25th. Zacks Research analyst Team expects that the company will post earnings per share of $1.06 for the quarter. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.56 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q3 2027 earnings at $1.22 EPS, Q4 2027 earnings at $1.30 EPS, FY2027 earnings at $4.55 EPS, Q1 2028 earnings at $1.14 EPS, Q2 2028 earnings at $1.19 EPS, Q3 2028 earnings at $1.38 EPS, Q4 2028 earnings at $1.35 EPS, FY2028 earnings at $5.06 EPS, Q1 2029 earnings at $1.20 EPS and FY2029 earnings at $5.25 EPS.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.89 by $0.09. The firm had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business's quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS.

A number of other analysts have also issued reports on the company. Oppenheimer lowered Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a report on Thursday, May 14th. Canaccord Genuity Group cut their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating for the company in a report on Friday, May 15th. Finally, Weiss Ratings cut Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, June 25th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Prestige Consumer Healthcare presently has an average rating of "Hold" and a consensus target price of $70.75.

Prestige Consumer Healthcare Trading Up 1.3%

Prestige Consumer Healthcare stock opened at $52.11 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The business's 50-day simple moving average is $50.03 and its 200-day simple moving average is $54.74. The firm has a market capitalization of $2.47 billion, a PE ratio of 14.60, a PEG ratio of 1.61 and a beta of 0.34. Prestige Consumer Healthcare has a 52 week low of $42.62 and a 52 week high of $71.07.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Prestige Consumer Healthcare in the second quarter valued at $370,187,000. California State Teachers Retirement System raised its stake in Prestige Consumer Healthcare by 4,490.7% during the second quarter. California State Teachers Retirement System now owns 2,630,954 shares of the company's stock worth $124,365,000 after acquiring an additional 2,573,644 shares in the last quarter. Rice Hall James & Associates LLC bought a new position in shares of Prestige Consumer Healthcare during the second quarter valued at $32,602,000. The Manufacturers Life Insurance Company bought a new position in shares of Prestige Consumer Healthcare during the second quarter valued at $31,135,000. Finally, Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at $36,954,000. 99.95% of the stock is currently owned by institutional investors.

Key Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Zacks projects earnings per share of $4.55 for FY2027, increasing to $5.06 in FY2028 and $5.25 in FY2029. That outlook suggests continued earnings growth for PBH, which could support investor interest over the longer term.
• Neutral Sentiment: The estimates include quarterly EPS forecasts of $1.06 for Q2 FY2027, $1.22 for Q3, and $1.30 for Q4, followed by $1.14, $1.19, $1.38, and $1.35 for FY2028’s quarters. These forecasts indicate relatively consistent profitability rather than a near-term earnings acceleration.
• Neutral Sentiment: Zacks’ FY2027 forecast of $4.55 is essentially in line with the current consensus estimate of $4.56, limiting the immediate upside from estimate revisions. The firm’s unchanged “Hold” rating also signals that valuation and growth prospects are viewed as fairly balanced.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source